PTC Taps Genzyme’s Global Reach, Pocketbook In Ultra-orphan Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
PTC124 offers new approach for treating lysosomal storage disorders central to Genzyme’s success, as well as other genetic diseases.
You may also be interested in...
Roche Inks A Second Deal With PTC Therapeutics, Pays $30M Upfront
The Big Pharma teams up with a biotech and a patient advocacy foundation to develop treatments for a rare genetic disorder.
AstraZeneca Digs For GEMS In Discovery Deal With PTC
The UK big pharma is the latest to strike deal with PTC for access to its drug discovery platform, this time in oncology.
AstraZeneca Digs For GEMS In Discovery Deal With PTC
The UK big pharma is the latest to strike deal with PTC for access to its drug discovery platform, this time in oncology.